Key terms

About ATNM

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ATNM news

Yesterday 7:30am ET Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM) Mar 26 10:55am ET Actinium Pharmaceuticals: A Strong Buy on Clinical Advancements and Strategic Positioning in the Radiopharmaceutical Sector Mar 21 11:18am ET Biotech Alert: Searches spiking for these stocks today Mar 20 12:50pm ET Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Actinium Pharmaceuticals (ATNM) Mar 20 11:06am ET Biotech Alert: Searches spiking for these stocks today Mar 19 1:32pm ET This radiopharma name seen as ‘poised for takeout’ following Fusion deal Mar 19 12:55pm ET Actinium Pharmaceuticals price target raised to $30 from $20 at Maxim Mar 19 12:45pm ET Actinium Pharmaceuticals: A Strong Buy Amidst Industry Interest and Strategic Advancements Mar 19 11:35am ET Radiopharmaceutical Growth and M&A Potential: Actinium Pharmaceuticals Buy Rating Justified Mar 19 11:23am ET Actinium positioned for takeout after Fusion deal, says H.C. Wainwright Mar 14 9:00am ET Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and P3 Health Partners (PIII) Mar 11 10:15am ET Buy Rating Affirmed: Strategic Advances and Clinical Potential Bolster Actinium Pharmaceuticals’ Outlook Mar 11 7:31am ET Actinium Pharmaceuticals launches Actinium-225 focused strategic initative Feb 28 11:59am ET Biotech Alert: Searches spiking for these stocks today Feb 28 11:59am ET Biotech Alert: Searches spiking for these stocks today Feb 27 7:45am ET Buy Rating Justified by Actinium Pharmaceuticals’ Iomab-B Clinical and Commercial Promise Feb 27 7:37am ET Iomab-B’s Breakthrough Potential in AML Treatment Bolsters Buy Rating for Actinium Pharmaceuticals Feb 26 7:42am ET Actinium Pharmaceuticals reported new analyses from Phase 3 SIERRA trial Feb 24 1:45pm ET Actinium Pharmaceuticals: A Strong Buy on Revolutionary Radiopharma and ADC Platform Potential Feb 23 11:15am ET Buy Rating Affirmed: Actinium Pharmaceuticals’ Iomab-B Shows Promising Efficacy and Market Potential Feb 23 7:51am ET Actinium Pharmaceuticals reports results from Phase 3 SIERRA trial of Iomab-B Feb 17 7:45am ET Buy Rating Affirmed: Actinium Pharmaceuticals Poised for Growth in Innovative Cancer Treatments Feb 16 7:55am ET Buy Rating Affirmed for Actinium Pharmaceuticals Amidst Promising Pipeline and Market Expansion Opportunities Jan 03 2:25pm ET Actinium Pharmaceuticals: A Strong Buy on Robust Financials and Promising Clinical Advances

No recent news articles are available for ATNM

No recent press releases are available for ATNM

ATNM Financials

1-year income & revenue

Key terms

ATNM Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ATNM Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms